

Accepted Manuscript

Liver fibrosis: Direct antifibrotic agents and targeted therapies

Detlef Schuppan, Muhammad Ashfaq-Khan, Ai Ting Yang, Yong
Ook Kim



PII: S0945-053X(18)30160-4
DOI: [doi:10.1016/j.matbio.2018.04.006](https://doi.org/10.1016/j.matbio.2018.04.006)
Reference: MATBIO 1480

To appear in:

Received date: 8 April 2018
Revised date: 10 April 2018
Accepted date: 11 April 2018

Please cite this article as: Detlef Schuppan, Muhammad Ashfaq-Khan, Ai Ting Yang, Yong Ook Kim , Liver fibrosis: Direct antifibrotic agents and targeted therapies. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. *Matbio*(2017), doi:[10.1016/j.matbio.2018.04.006](https://doi.org/10.1016/j.matbio.2018.04.006)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Liver fibrosis: Direct antifibrotic agents and targeted therapies

Detlef Schuppan^{1,2,*}, Muhammad Ashfaq-Khan¹, Ai Ting Yang¹, Yong Ook Kim¹

¹Institute of Translational Immunology and Research Center for Immunotherapy; University of Mainz Medical Center, Mainz, Germany; ²Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA

*Corresponding author. Address: Institute of Translational Immunology and Research, Center for Immunotherapy, University Medical Center of the Johannes Gutenberg, University Mainz, Langenbeckstraße 1, 55131 Mainz, Germany. Tel.: +49 (0) 6131 17-7356; fax: +49 (0) 6131 17-7357. *Email address:* dschuppa@bidmc.harvard.edu (D. Schuppan)

Key words: Antifibrotic, biomarker, cirrhosis, chemokine, cholangiocyte, collagen, crosslink, cytokine, DDR1, DDR2, extracellular matrix, FAP, fibroblast, fibroblast activation protein, fibrogenesis, fibrolysis, fibrosis, integrin, latent TGFbeta binding protein, liver, lipoapoptosis, Lox, Loxl2, macrophage, myofibroblast, NAFLD, NASH, progenitor cell, progression, regression, second hit, serum marker, stellate cell, TGFbeta, TG2, therapy, transglutaminase

Abbreviations: ASO, antisense oligonucleotide; ECM, extracellular matrix; DDR, discoidin domain receptor; FAP, fibroblast activation protein; HSC, hepatic stellate cell(s); MF, myofibroblast(s); Lox, lysyl oxidase; Loxl, lysyl oxidase like; MMP, matrix metalloproteinase; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PDGF, platelet derived growth factor; siRNA, small interfering RNA; TGF, transforming growth factor; TG2, transglutaminase 2; TIMP, tissue inhibitor of metalloproteinases

Download English Version:

<https://daneshyari.com/en/article/8455025>

Download Persian Version:

<https://daneshyari.com/article/8455025>

[Daneshyari.com](https://daneshyari.com)